Evidence map›Paper›PMID 25013388›Full record

ArticleGastroenterology & hepatology2014

Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy.

Ying Lu, Athos Bousvaros

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025
    Guideline
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Vaccination in the Elderly and IBD.Current treatment options in gastroenterology · 2019
    Review
  10. Review
  11. Pediatric Crohn's Disease in Bahrain.Oman medical journal · 2018
    Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ying LuDr Lu is an assistant professor in the Division of Pediatric Gastroenterology at Cohen Children's Medical Center of New York at Hofstra North Shore-Long Island Jewish School of Medicine in Lake Success, New York. Dr Bousvaros is a pediatric gastroenterologist in the Division of Pediatric Gastroenterology, Hepatology, and Nutrition and the associate director of the Inflammatory Bowel Disease Center at Boston Children's Hospital in Boston, Massachusetts. He is also an associate professor of medicine at Harvard University in Boston, Massachusetts.
Athos BousvarosDr Lu is an assistant professor in the Division of Pediatric Gastroenterology at Cohen Children's Medical Center of New York at Hofstra North Shore-Long Island Jewish School of Medicine in Lake Success, New York. Dr Bousvaros is a pediatric gastroenterologist in the Division of Pediatric Gastroenterology, Hepatology, and Nutrition and the associate director of the Inflammatory Bowel Disease Center at Boston Children's Hospital in Boston, Massachusetts. He is also an associate professor of medicine at Harvard University in Boston, Massachusetts.
Boston Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vast majority of patients with inflammatory bowel disease (IBD) will receive immunosuppressive therapy at some point for their disease, whether for the short term (such as a course of corticosteroids) or long term (such as maintenance therapy with immunomodulators or biologics). The systemic immunosuppression places patients at increased risk for infections. Therefore, it is important that patients are up-to-date with immunizations to minimize vaccine-preventable infections. However, the literature shows that the rate of immunization in patients with IBD is low. Ideally, the vaccination status is checked at diagnosis, and patients are immunized with the vaccines they need. Drawing titers is helpful in cases in which vaccination history is unclear or to confirm that titers are at an adequate level in cases in which patients have been vaccinated. Current guidelines recommend that patients with IBD follow the same routine immunization schedule as healthy children, but patients should not be administered live vaccines if they are receiving immunosuppressive therapy. Therefore, it is ideal to administer any necessary vaccinations as early as possible, prior to starting immunosuppressive therapy. Patients may receive inactivated vaccines regardless of immunosuppressive status. The IBD literature suggests that inactivated vaccines are safe and do not worsen disease activity. In general, patients with IBD mount an immune response to vaccines, but the response may be lower if patients are receiving immunosuppressive therapy, especially tumor necrosis factor inhibitors.

Indexed as

Crohn’s diseaseimmunizationimmunosuppressionInflammatory bowel diseaseulcerative colitisvaccine

Identifiers

PMID25013388
PMCPMC4080872
OpenAlexW100685863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.